CD274 and non-small cell lung carcinoma: Therefore, in October 2021 (56), the United States Food and Drug Administration (FDA) approved atezolizumab monotherapy as adjuvant therapy in patients with PD-L1-positive (TC ≥1%) stage II-IIIA NSCLC after surgical resection and platinum-based chemotherapy.